A new derivative of coumarin, a natural plant product abundant in cinnamon, could hold the key to healthy aging. Researchers at the Buck Institute have shown that it extended life span and prevented neurodegenerative disease in worms and mice. The drug, a TFEB gene inducer called MIC, promoted mitochondria recycling (mitophagy) but also interacted with lysosomes, which could have multiple applications. The scientists published the results of this aging and mitophagy study on Nov. 13, 2023, in Nature Aging.
Some strategies seek to alter molecular mechanisms that can redirect the programmed death of tumor cells. If you can’t selectively eliminate them or stop their proliferation, ask them to die, but don’t tell any other cells. That is the idea proposed by a group of researchers participating in a Chinese-American collaboration for the design of the new drug N6F11. In a mouse model, the compound caused death by ferroptosis only of cancer cells without altering immune cells.
Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.
The largest genetic analysis of abdominal aortic aneurysm (AAA) carried out to date has identified almost 100 new risk variants linked to the disorder. The study also highlighted a possible therapeutic target for this pathology that, at the moment, has no treatment. AAA affects 4% of people over 65 years of age in the U.S. and causes 41,000 deaths per year. The incidence is three to four times higher in men than in women.
The Congress of the European Society of Medical Oncology (ESMO) held in Madrid from Oct. 20 to 24, 2023, could well add the letter W to its acronym after the four sessions on gynecological cancer that could represent a milestone in the lives of all women who suffer from cervical, ovarian, or endometrial cancer.
To understand the human brain, an international consortium of scientists has created the most complete atlas of this organ to date. The map reveals the anatomy, the architecture of the tissues, how or where each cell is, their function, gene expression and regulation. On Oct. 12, 2023, Science and Science Advances published a group of 21 studies that unveiled the map of the human brain, as well as the brains of nonhuman primates and mice, cell by cell, for an adult model and for the different stages of development.
Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.
Artificial intelligence (AI) is in full development, and advances are already used in many fields, including medicine. In oncology, these tools can identify a tumor in an image with 99% accuracy. But they can also miss it if the algorithm was not developed with the right data or the correct decisions. The 2023 European Society for Medical Oncology (ESMO) Congress brought together in Madrid doctors and deep learning experts to discuss the challenges and advances of AI in this area. And what’s better than asking an AI what its trainer has told it about AI?
Some cancers with a poor prognosis have had no new treatments in decades. Advances in the genetic characterization of these tumors now offer a range of possibilities for the development of new therapies that could completely change the quality of life and survival of these patients.
The mRNA technology used in vaccines against viral infections could also be developed for cancer therapies. A group of scientists has designed a circular RNA (circRNA) encapsulated in lipid nanoparticles (LNPs) that acts in the mitochondria of tumor cells through the protein gasdermin-D (GSDMD) and reduces adenocarcinoma. The work was published on Oct. 16, 2023, in Nature Cancer.